Literature DB >> 28622443

miR-2909 regulates ISGylation system via STAT1 signalling through negative regulation of SOCS3 in prostate cancer.

Shiekh Gazalla Ayub1, Deepak Kaul1.   

Abstract

One of the well-document strategies adopted by tumour cells for progression is to evade immune surveillance mechanisms. An understanding of the tight interaction between immunity and progression of cancer can provide novel treatment options for different malignancies including prostate cancer (PCa). Here, we have shown that AATF genome encoded miR-2909, known to play role both in immunity and cancer upregulates various interferon stimulating genes (ISGs) including ISGylation system through STAT1. Our results revealed that miR-2909 up-regulates STAT1 through negative regulation of SOCS3 and not through up-regulation of Type 1 interferon (IFN) production. It was observed that inhibition of ISGylation reduced the proliferation potential of PCa cells. Furthermore, androgens were found to negatively regulate ISGylation in LNCaP cells through androgen receptor signalling independently of miR-2909. TGF-β mediated SMAD3 signalling was also seen to be suppressed by miR-2909 through induction of SMAD7 via enhanced STAT1 expression. Collectively, these studies suggest that miR-2909 could play a vital role in prostate carcinogenesis through modulation of ISGylation system and TGFβ signalling via STAT1.
© 2017 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  ISG15; SOCS3; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28622443     DOI: 10.1111/andr.12374

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  6 in total

1.  Cellular miR-2909 RNomics governs the genes that ensure immune checkpoint regulation.

Authors:  Deepak Kaul; Deepti Malik; Sameena Wani
Journal:  Mol Cell Biochem       Date:  2018-06-20       Impact factor: 3.396

2.  The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus.

Authors:  Johanna Giuranna; Anna-Lena Volckmar; Anna Heinen; Triinu Peters; Börge Schmidt; Anne Spieker; Helena Straub; Harald Grallert; Timo D Müller; Jochen Antel; Ute Haußmann; Hans Klafki; Liangyou Rui; Johannes Hebebrand; Anke Hinney
Journal:  Obes Facts       Date:  2018-04-10       Impact factor: 3.942

3.  LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway.

Authors:  Chuigong Yu; Yu Fan; Yu Zhang; Lupeng Liu; Gang Guo
Journal:  Cancer Cell Int       Date:  2022-07-10       Impact factor: 6.429

4.  Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.

Authors:  Fang Lyu; Yunxue Li; Zhecheng Yan; Qingliu He; Lulin Cheng; Pu Zhang; Bing Liu; Chunyu Liu; Yarong Song; Yifei Xing
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 8.440

Review 5.  Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance.

Authors:  Shuya Liu; Saber Imani; Youcai Deng; Janak L Pathak; Qinglian Wen; Yue Chen; Jingbo Wu
Journal:  Onco Targets Ther       Date:  2020-06-24       Impact factor: 4.147

6.  ISGylation of EMD promotes its interaction with PDHA to inhibit aerobic oxidation in lung adenocarcinoma.

Authors:  Congcong Zhang; Jiangtao Cui; Leiqun Cao; Xiaoting Tian; Yayou Miao; Yikun Wang; Shiyu Qiu; Wanxin Guo; Lifang Ma; Jinjing Xia; Xiao Zhang
Journal:  J Cell Mol Med       Date:  2022-09-07       Impact factor: 5.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.